KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Acadia Pharmaceuticals (ACAD) Other Gross PP&E Adjustments (2016 - 2025)

Acadia Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 15 years, most recently at -$68.4 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$68.4 million for Q4 2025, up 18.22% from a year ago — trailing twelve months through Dec 2025 was -$68.4 million (up 18.22% YoY), and the annual figure for FY2025 was -$68.4 million, up 18.22%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$68.4 million at Acadia Pharmaceuticals, up from -$79.5 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for ACAD hit a ceiling of -$64.6 million in Q2 2023 and a floor of -$95.2 million in Q4 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$76.2 million (2024), compared with a mean of -$76.3 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 181.27% in 2021 and later rose 18.22% in 2025.
  • Acadia Pharmaceuticals' Other Gross PP&E Adjustments stood at -$95.2 million in 2021, then grew by 2.2% to -$93.1 million in 2022, then rose by 4.73% to -$88.7 million in 2023, then rose by 5.79% to -$83.6 million in 2024, then grew by 18.22% to -$68.4 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$68.4 million (Q4 2025), -$79.5 million (Q3 2025), and -$81.0 million (Q2 2025) per Business Quant data.